在阿尔茨海默氏症患者的血管肝素硫酸和胺β
Ilayda Ozsan McMillan1, Marla Gearing2, Lianchun Wang1
1Department of Molecular Pharmacology & Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33613, USA.
International journal of molecular sciences
|April 13, 2024
概括
阿尔茨海默氏症患者患有严重的大脑粉样蛋白血管病变,大脑血管中的肝素硫酸盐 (HS) 含量增加,与粉样蛋白-β (Aβ) 和ApoE4相关. 这表明HS可能在阿尔茨海默病 (AD) 血管病理学中发挥作用.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β (Aβ) 积累和脑粉样血管病变 (CAA).
- 肝素硫酸盐 (HS) 是脑血管系统的一个组成部分,但其在AD和CAA中的作用尚未完全理解.
研究的目的:
- 为了研究阿尔茨海默病 (AD) 患者的大脑血管系统中的肝硫酸盐 (HS) 表达.
- 检查HS与粉样β (Aβ),性别和AD和CAA中的ApoE4基因型的关联.
主要方法:
- 使用共聚焦成像来分析HS表达及其与Aβ.同位的同位化.
- 评估HS表达与CAA严重程度,性别和ApoE4基因型有关.
主要成果:
- 在AD患有严重CAA的AD患者的大脑血管系统中观察到HS水平升高和HS-Aβ局部化增加.
- 在严重的CAA中,在男性中观察到HS极化表达的逆转和较低的HS水平.
- 在严重的CAA中,ApoE4携带者表现出脑血管Aβ升高和HS升高的趋势.
结论:
- 脑血管肝素硫酸盐 (HS) 可能在脑粉样血管病变 (CAA) 和阿尔茨海默病 (AD) 病理学的发展中发挥重要作用.
- 对于HS,Aβ,ApoE和血管因素之间的相互作用,需要进一步研究AD的潜在治疗策略.
相关概念视频
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183


